MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
-0.010
-0.41%
After Hours: 2.450 +0.05 +2.08% 19:58 01/26 EST
OPEN
2.510
PREV CLOSE
2.410
HIGH
2.740
LOW
2.290
VOLUME
16.67M
TURNOVER
--
52 WEEK HIGH
2.940
52 WEEK LOW
0.7014
MARKET CAP
251.95M
P/E (TTM)
-4.2576
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
8-K: ACELRX PHARMACEUTICALS INC
acrx20210121_8k.htm false 0001427925 0001427925 2021-01-19...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
DJ AcelRx Pharmaceuticals Shares Drop 17% After Public Offering Prices
Dow Jones · 6d ago
SWN, MARA, LAC and BNGO among midday movers
Gainers: Obalon Therapeutics (OBLN) +438%.Caladrius Biosciences (CLBS) +121%.Adamis Pharmaceuticals (ADMP) +72%.Steel Connect (STCN) +54%.Titan Medical (TMDI) +52%.Tiziana Life Sciences (TLSA) +50%.Iterum Therapeutics (ITRM) +40%.Dare Bioscience (DARE) +33...
Seekingalpha · 6d ago
Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers
Gainers: Obalon Therapeutics (OBLN) +181%, Caladrius Biosciences (CLBS) +137%, Titan Medical (TMDI) +36%, Tiziana Life Sciences (TLSA) +31%, Gritstone Oncology (GRTS) +12%.Losers: BioLineRx (BLRX) -24%, AcelRx Pharmaceuticals (ACRX) -17%, Bionano Genomics ...
Seekingalpha · 6d ago
AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock
, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its unde...
PR Newswire - PRF · 6d ago
AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public off...
PR Newswire · 6d ago
DSS, MARA and BNGO among premarket losers
Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study
Seekingalpha · 6d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRX. Analyze the recent business situations of Acelrx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRX stock price target is 5.46 with a high estimate of 9.00 and a low estimate of 0.8300.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 23.37M
% Owned: 23.65%
Shares Outstanding: 104.98M
TypeInstitutionsShares
Increased
23
1.44M
New
16
3.73M
Decreased
20
616.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Independent Director
Adrian Adams
Chief Executive Officer/Director
Vincent Angotti
Co-Founder/Director
Pamela Palmer
Chief Financial Officer
Raffi Asadorian
Other
Badri Dasu
Independent Director
Richard Afable
Independent Director
Mark Edwards
Independent Director
Stephen Hoffman
Independent Director
Howard Rosen
Independent Director
Mark Wan
  • Dividends
  • Splits
  • Insider Activity
No Data
About ACRX
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.